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The mechanisms of human preterm labour appear inextricably linked to cytokine biosynthesis by gestational tissues. In turn,
cytokineproductionbygestationaltissueshasbeenshowntoberegulatedbyepigeneticmechanisms.Inthispaper,wedemonstrate
that cytokine production in gestational tissues is regulated epigenetically in a tissue-speciﬁc manner. Furthermore, we show that
treatment with a histone deacetylation inhibitor can partially abrogate LPS-stimulated TNFα production in villous placenta but
not amnion. LPS treatment signiﬁcantly (P<0.05) increased the production of IL-1β (∼10–34-fold), TNFα (∼23–>100-fold)
and IL10 (∼6–10-fold) after 24h of treatment in villous explants, as expected. There were no signiﬁcant LPS eﬀects on IL1Ra
production. AZA treatment did not have any signiﬁcant eﬀect on any cytokines’ production tested either alone or in combination
with LPS. Interestingly, however, the stimulatory eﬀects of LPS on TNFα production were partially mitigated (P<0.05) by TSA
treatment in villous explants. We suggest caution in the consideration of histone deacetylation inhibitors in pregnancy due to the
diﬀerent responses in gestational tissues.
1.Introduction
Preterm birth is the leading cause of neonatal death world-
wide with one million deaths directly resulting from prema-
ture birth. More children under the age of 5 years die due to
preterm birth than to AIDS, malaria, or tuberculosis [1]. The
rate of preterm birth in Australia is gradually increasing [2].
Recently, the importance of epigenetics as a regulator of gene
expression has become apparent and, potentially, epigenetic
diﬀerences are driving gene expression leading to preterm
birth.
Epigenetics is the process by which interactions between
genes and environment lead to stable changes in phenotype
[3].Epigeneticchanges(e.g.,DNAmethylation,covalenthis-
tone modiﬁcations, etc.) are by deﬁnition heritable, mean-
ing that eﬀects brought about by the environment at critical
periods of development (such as gestation) can have long-
term detrimental consequences [4]. Indeed, certain epige-
netic changes are passed between generations which might
explain some of the familial and intergenerational eﬀects
observed for preterm birth [5]. Importantly and in contrast
to genetic inheritance, epigenetic heritability is potentially
reversible [6]. An epigenomics approach, thus, opens new
avenues for therapeutic interventions.
Epigenetic information is conveyed via a synergistic in-
teraction between mitotically heritable patterns of DNA me-
thylation and histone-mediated modiﬁcations to the chro-
matin structure [7]. In mammals, DNA methylation pri-
marily involves the addition of methyl groups to cytosine
residuespresent in aCpG dinucleotide. Hypermethylation of
promoter regions of genes is typically associated with tran-
scriptional repression whereas hypomethylation is usually
permissive for gene activity. Histone modiﬁcations consist
of a plethora of enzymatic modiﬁcations including acety-
lation, methylation, ubiquitination, and phosphorylation of
diﬀerent amino acids in the N terminal tails of histone pro-
teins, the combination of which is thought to determine
the local conformational state of the chromatin. Currently,
over 60 diﬀerent histone modiﬁcations have been identiﬁed
although actual numbers are likely to be signiﬁcantly higher2 Mediators of Inﬂammation
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Figure 1: Eﬀect of AZA and TSA on cytokine production by villous explants in the presence or absence of LPS. The levels of cytokines were
measured by ELISA. The y-axis shows the rate of mean IL1β (a), TNFα (b), IL10 (c), and IL1Ra (d) production (as % basal control values),
normalized against the wet tissue weight, and the x-axis shows the diﬀerent treatment groups. Error bars represent 1 S.E.M.
∗P < 0.05,
n = 3.
[8]. Histone modiﬁcations are generally considered a less
stable epigenetic mark than DNA methylation. Recent work
has clearly demonstrated that epigenetic marks determine
time- (temporal) and tissue-speciﬁc (spatial) aspects of gene
expression throughout development. In contrast, others
mightcarryanepigeneticsignaturethatislesssensitivetothe
normal stimuli of labour, therefore, leading to dysfunctional
labour or postdates delivery. The environment presumably
playsacrucialroleinbringingabouttheseepigeneticchanges
that are critical for the safe passage of gestation and later
outcomes. An increasing number of diverse factors are now
known to epigenetically regulate genes, including age [9],
inﬂammation [10], gender [11], genotype [12], stress [13],
nutrition [14], metabolism [15], drugs [16], and infection
[17], thus heightening the relevance of the study of the
epigenetics of preterm birth.
Both classes of epigenetic modiﬁcation (e.g., DNA meth-
ylation and covalent histone modiﬁcations) can be reversed
through treatment with a chemical inhibitor: 2 -deoxy-5-az-
acytidine (AZA) that inhibits DNA methylation leading to
global hypomethylation of DNA, while treatment with an in-
hibitor of histone deacetylation such as trichostatin A (TSA)
leads to increased levels of histone acetylation. In both cases,
intervention favours the transcriptionally active epigenetic
state.
We demonstrated in an earlier study [16] that the com-
bination treatment of human choriodecidual explants with
AZAandTSAleadstoamassiveincreaseinIL-1β production
in response to LPS. In the present study, we extend those
ﬁndings to amnion and villous placenta.
2.MaterialsandMethods
2.1. Reagents. Lipopolysaccharide (LPS), 5-aza-2 -deoxycy-
tidine (AZA), and trichostatin A (TSA) were purchased from
S i g m aC h e m i c a l( S t .L o u i s ,M O ) .C u l t u r em e d i aa n df e t a l
calf serum (FBS) were from Life Technologies (Carlsbad, CA,
USA). Human IL1β,T N F α, IL10, and IL1Ra ELISA kits were
purchased from BD Bio Sciences.Mediators of Inﬂammation 3
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Figure 2: Eﬀect of AZA and TSA on cytokine production by amnion explants in the presence or absence of LPS. The levels of cytokines were
measured by ELISA. The y-axis shows the rate of mean IL1 β (a), TNFα (b), IL10 (c), and IL1Ra (d) production (as % basal control values),
normalized against the wet tissue weight, and the x-axis shows the diﬀerent treatment groups. Error bars represent 1 S.E.M.
2.2. Explant Cultures. Placental tissues were collected from
women undergoing elective caesarean section at term, with
the approval of the NorthernX Regional Ethics Committee.
Three individual placentae from singleton pregnancies of
healthy nonsmoking mothers were used in the study. In
triplicate, villous and amnion tissues explants were cultured
in 12-well plates (three pieces of tissue to a well) in
DMEM/F12 media supplemented with glutamax, 10% FBS,
and 1% Antibiotic-antimycotic and incubated at 37◦Ci n
humid 5% CO2/95% air for 24h (modiﬁed from [18, 19]).
Explant treatments included the use of 5-aza-2 -deoxy-
cytidine (AZA), which inhibits DNA methylation, and/or
Trichostatin A (TSA) which inhibits histone deacetylation.
Doses and times were chosen to be consistent with published
literature [18, 20]. 24 hours following placental dissection,
themediawerereplacedwithserum-freemedia(DMEM/F12
with glutamax and 0.1% Bovine gamma globulin and 1%
Antibiotic-antimycotic medium). Explants were treated with
either 200nM AZA alone, TSA (300nM) alone, 5μMA Z A
with TSA (300nM), or the DMSO carrier and cultured
for 48h, with media refreshed once during this time. This
represented a 48h preincubation ± AZA (the action of AZA
ispassiveandrequirescelldivisionforaction).Thetreatment
period commenced 72h postdissection and consisted of the
addition of 300nM TSA or DMSO carrier in fresh media,
in the presence or absence of LPS (5μg/mL), to the explants
for a duration of 24h. The media were collected following
the treatment and the wet weight of the tissue in each well
determined so that cytokine production rates could be nor-
malized. Measurements of pro- (IL1β,T N F α) and anti-in-
ﬂammatory (IL10, IL1Ra) cytokines were conducted on cul-
turedmediausingELISAsaccordingtomanufacturers’speci-
ﬁcations.
2.3. Statistical Analysis. Production rates of cytokines were
calculated as picograms per gram wet tissue weight per 24h
andarepresentedas%basalcontrolvalues(means±SE,n =
3). Statistical signiﬁcance was determined by ANOVA, and
P<0.05 was considered to be signiﬁcant.4 Mediators of Inﬂammation
3. Results
3.1. Eﬀect of AZA and TSA on Cytokine Production by Villous
Explants in the Presence or Absence of LPS. LPS treatment
signiﬁcantly (P<0.05) increased the production of IL-1β
(∼10–34-fold), TNFα (∼23–>100-fold) and IL10 (∼6–10-
fold) after 24h of treatment in villous explants, as expected.
There were no signiﬁcant LPS eﬀects on IL1Ra production.
AZA treatment did not have any signiﬁcant eﬀect on any
cytokines’ production tested either alone or in combination
with LPS. Interestingly, however, the stimulatory eﬀects of
LPS on TNFα production were partially mitigated (P<0.05)
by TSA treatment in villous explants.
3.2. Eﬀect of AZA and TSA on Cytokine Production by Amnion
explants in the Presence or Absence of LPS. Neither LPS nor
the TSA or AZA had any signiﬁcant eﬀect on the cytokine
production in amnion explants after 24h of treatment.
4. Discussion
Conceivably, epigenetic modiﬁcations (e.g., DNA methyla-
tion and covalent histone modiﬁcations) might render indi-
v i d u a l sm o r eo rl e s ss u s c e p t i b l et oe i t h e rt e r mo rp r e t e r m
birth by modulating the expression of genes that are eﬀectors
of the parturition pathway, for example, the contraction-as-
sociated proteins, COX-2, oxytocin, and prostaglandin re-
ceptors in myometrium [20]. Thus, some individuals may
have a sensitive epigenetic phenotype that leads to an in-
creased susceptibility to preterm labour. Global DNA meth-
ylation is increased in preterm preeclamptic placentae [21].
In this study, in conjunction with our previous work [18]w e
have shown that epigenetic regulation of cytokine produc-
tion is tissue speciﬁc in gestational tissues. Caution of course
should be exercised in the comparison of noncontempora-
neous data. In choriodecidua AZA/TSA treatment resulted
in a massive increase in IL-1β production in response to LPS
whereas in amnion and villous placenta this did not occur
although a small positive trend in mean production was
noted (Figures 1 and 2). Our ﬁnding of TSA mitigation of
LPS-stimulated TNFα production is most fascinating. This
raises the question of TSA-like moieties being developed
to attenuate inﬂammatory process in the human placenta.
The disadvantage of such an approach is, of course, the
enhancement of IL-1β production in choriodecidua by such
an agent [18]. The tissue-speciﬁc nature of these regulato-
ry mechanisms means that we must be cautious in our ap-
proach to such matters.
Amnion clearly does not respond to the inﬂammatory
challenge of LPS although it remains a signiﬁcant source of
cytokine production and once activated can respond vigor-
ously to modiﬁcations of the cytokine environment [22–25].
Villous placenta seems crudely to be more active in pro-
inﬂammatory cytokine biosynthesis than anti-inﬂammatory
cytokine biosynthesis. This is clearly dangerous for the fetus
and may play a role in the fetal inﬂammatory syndrome [26],
although clearly direct evidence must be obtained before
conclusions are drawn.
5. Conclusions
Cytokine production in gestational tissues is regulated epige-
netically in a tissue-speciﬁc manner. Furthermore, treatment
with a histone deacetylation inhibitor can partially abrogate
LPS-stimulated TNFα production in villous placenta but not
amnion.
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